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Uremic serum enhances scavenger receptor expression and activity in
the human monocytic cell line U937. The macrophage scavenger receptor
(SR) plays a leading role in atherogenesis, but little is known about the
relevance of SR to atherosclerosis in uremia. In this study, the impact of
uremic serum on SR expression and activity was examined in the human
monocytic cell line U937. The cells were cultured with serum from ten
healthy subjects, ten hemodialysis (HD) and ten continuous ambulatory
peritoneal dialysis (CAPD) patients. SR mRNA expression was examined
using reverse transcriptase-polymerase chain reaction followed by South-
ern blot. SR protein amount was evaluated by ligand blot. SR activity was
analyzed by cellular uptake of fluorescently labeled acetylated low-density
lipoprotein using flow cytometly. Uremic serum dose-dependently en-
hanced SR activity primarily by increasing the amount of receptor protein.
Heat-inactivated uremic serum had a stimulatory effect, but ultrafiltrate of
uremic serum, which included molecules with a molecular weight less than
ten kDa, had no effect. The serum levels of macrophage-colony stimulat-
ing factor (M-CSF), an activator of SR, were fourfold higher in uremia
and significantly correlated with SR activity in cells treated with uremic
serum. Pre-treatment of uremic serum with a neutralizing antibody to
M-CSF abolished the effect of uremic serum on SR activity. In conclusion,
uremic serum contains a factor(s) that enhances SR expression and
activity in U937 cells. Elevated M-CSF in uremic serum could be
responsible for this enhancement.
Monocyte adhesion, migration into the endothelium of arteries,
and intracellular accumulation of modified low-density lipopro-
tein (LDL) are key steps in the early stages of atherogenesis [1, 2].
The scavenger receptor (SR) mediates uptake of modified LDL
such as oxidized LDL (ox-LDL) by macrophages. The accumula-
tion of lipids via this process leads to foam cell formation in
developing atherosclerotic plaques [3, 4]. Two isoforms of the
macrophage SR, type I and type II, are capable of binding and
internalizing modified LDL, hut it remains unknown whether
there are fine functional differences between the two types [5].
Furthermore, SR has recently been identified as an adhesion
molecule that mediates cation independent adhesion of mono-
cyte-macrophages to the endothelium [6].
The regulatory mechanisms of SR expression and activity have
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recently come under investigation. A number of factors have been
shown to affect macrophage SR activity of cells cultured in vitro.
These include phorbol esters, endotoxin, macrophage-colony-
stimulating factor (M-CSF), platelet secretory products, trans-
forming growth factor-1, interferon-y, and tumor necrosis fac-
tor-a [7—13]. M-CSF and platelet secretory products are of special
interest because they are constitutively secreted into human
serum and can stimulate SR expression and activity in monocyte-
macrophage lineage cells [9, 14, 15]. In particular, serum levels of
M-CSF have been shown to be elevated in dialysis patients [16, 171
and even low concentrations of recombinant M-CSF (rM-CSF)
stimulate SR activity in human monocyte-macrophages cultured
in Vitro [9].
Atherosclerosis is considered to be accelerated in dialysis
patients [18, 19] and cardiovascular disease is the most critical
cause of morbidity and mortality in these patients [20, 21]. LDL
from uremic patients is more susceptible to oxidation stress than
LDL from control subjects [22] and uremic patients have in-
creased titers of anti-ox-LDL antibody [23]. It is likely, therefore,
that SR function is of greater importance to atherogenesis in
uremic patients than in healthy subjects. We have previously
shown that SR mRNA expression and activity are enhanced in
primary macrophages from dialysis patients when cultured in Vitro
in the presence of autologous serum [24]. These results suggest
that SR alone, or possibly in condition with elevated ox-LDL
levels, plays a key role in the mechanism of uremia-associated
atherosclerosis.
SR activity may be regulated by components in uremic serum
since renal failure often induces increased accumulation of some
of the substances mentioned above [16, 17, 25]. Our previous
results could be due to components in the autologous serum, the
intrinsic characteristics of uremic macrophages per Sc, or a com-
bination of the two. Therefore, we investigated the possible
impact of uremic serum obtained from dialysis patients on SR
expression and activity in the standardized in Vitro cultured
macrophage-like cell line U937. We now report that uremic serum
can enhance SR activity by increasing the amount of receptor
protein in U937 cells, probably via a heat-stable factor(s) with a
molecular weight above 10 kDa. In addition, the elevated concen-
tration of M-CSF in uremic serum is possibly responsible for the
enhanced SR activity in the dialysis patients.
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Table 1. Clinical and laboratory characteristics of dialysis patients
HD patients
(N=10)
CAPD patients
(N=10)
Age years 43.4 12.0 42.4 7.2
Duration of dialysis months 31.2 31.8 24.9 17.1
Serum chemistry
Albumin glliter; 35—46 33.9 3.87 32.3 4.57
Urea mmol/liter; 3.0—7.5 25.8 6.85 17.5 8.45
Creatinine unol/liter; <120 904 196 727 225
Total cholesterol mmol/liter; <6.8 5.7 1.08 6.8 0.97
Triglycerides mmol/liter; <2.2 2.8 1.2 2.0 0.47
respectively), and 2 mrvi L-glutamine at 37°C in an atmosphere of
5% CO. in each experiment, 1 X iO U937 cells/mi were
pre-cultured in fresh medium for seven days in a 250 ml culture
flask (Nunclon, Kamstrup, Denmark). The cells were then col-
lected by centrifugation, washed three times in PBS, resuspended
at 1 x 106 cells/mi and cultured for three days in fresh supple-
mented medium containing 20% of an individual uremic or
control serum (instead of 10% FCS) and polymyxin B 50 ig/ml
(Sigma, St. Louis, MO, USA). These cells were used for flow
cytometry analysis, reverse transcriptase-polymerase chain reac-
tion (RT-PCR), and ligand blotting.
Flow cytometly analysis
Methods
Sample collection and preparation
Normal control serum and plasma were obtained from ten
healthy volunteers (3 females, 7 males, mean age 41.6 7.4
years). Uremic serum and plasma were obtained from non-
diabetic dialysis patients on maintenance hemodialysis (HD) or
continuous ambulatory peritoneal dialysis (CAPD) treatment.
Ten HD patients (5 females, 5 males, mean age 43.4 12.0 years)
were bled at the beginning of dialysis, before the administration of
anticoagulants. Ten CAPD patients (5 females, 5 males, mean age
42.4 7.2 years) were bled before the first bag exchange of the
day.
Blood was drawn either with or without anticoagulant for
obtaining plasma or serum, respectively. Serum was obtained by
centrifuging the blood after clotting at room temperature. Plasma
was separated by centrifuging the heparin-containing blood. The
plasma was dialyzed at 4°C against phosphate-buffered saline
(PBS) containing CaCl2 (0.1 g/liter) to remove the fibrin clot
before being used in cell culture experiments. None of the
patients had received lipid-lowering drugs, steroids, or immuno-
suppressants. Serum lipid levels of the healthy subjects were
within normal limits (total cholesterol 5.9 0.8 mmol/liter,
triglycerides 1.6 0.4 mmol/liter). The clinical characteristics of
the dialysis patients who contributed their blood are listed in
Table 1. Ultrafiltrates (UFs) of uremic serum from ten other HD
patients (mean age 53.5 15.9 years) were collected during the
first thirty minutes of their regular HD treatments by the extra-
corporeal ultrafiltration method using cellulose acetate mem-
branes with a molecular cut off point of 10 kDa (CA 170 G
dialyzer; Baxter Healthcare, Deerfield, IL, USA). In some exper-
iments, a mixture of individual HD sera, healthy sera, CAPD sera,
and UFs were used. In each mixture, four sera or UFs were mixed
together in equal volumes. Those samples were randomly chosen
from the individual samples described above, Heat-inactivation of
the uremic serum was performed at 56°C for 30 minutes. All
samples were filtered through 0.45 rm filters and stored at —70°C
until use. The study was approved by the Ethics Committee of the
Karolinska Institute at Huddinge University Hospital. Informed
consent was obtained from all subjects.
cells and cell culture
The U937 cell line was purchased from the American Type
Culture Collection (Rockvillc, MD, USA) and was cultured in
RPM! 1640 medium (Gibco, Grand Island, NY, USA) supple-
mented with 10% heat-inactivated fetal calf serum (FCS), 20 mt
Hepes buffer, penicillin/streptomycin (100 U/mI and 100 g/ml,
A total of 2 X 106 cells were harvested from the culture flask,
washed three times with PBS and incubated with 10 jtg/ml of
1,1 '-dioctadecyl-3,3 ',3,3'-tetramethyl-indocarbocyanine (Dii) la-
beled or unlabeled acetylated (Ac)-LDL (Biogenesis, Bournemouth,
UK) dissolved in 200 tl RPMI medium containing 10% lipopro-
tein-deficient serum at 37°C for three hours. Ac-LDL is a specific
and sensitive ligand for both types of SRs [1, 3]. After incubation,
the cells were washed three times, fixed in 2% formaldehyde in
PBS, and analyzed on a FACS scan flow cytometer (Becton
Dickinson, San Jose, CA, USA) equipped with an argon laser
operating at 488 nm. The experiment was conducted in duplicate
unless otherwise stated. Forward angle and 90° light scatter gates
were established to exclude dead cells and cell debris from the
analysis. The instrument was periodically calibrated using 2.0 j.tm
microbeads (Becton Dickinson). Fluorescence signals from the
accumulated Dii in the cells were collected at 550 to 590 nm by
the red photomultiplier, converted to digital format and processed
for storage and display in one-parameter, log scale frequency
histogram. Five thousand cells were analyzed in each sample.
Autofluorescence signals from unlabeled cells were used as neg-
ative controls in each experiment. The specific mean fluorescence
intensity (sMFI) of Dil-labeled cells was calculated by subtracting
the autofluorescence intensity from the observed MFI of labeled
cells for quantitative evaluation of SR activity [12]. The average of
the duplicate determinations was used for statistical analyses.
Ligand blotting
Ligand blotting was performed with minor modification accord-
ing to the methods of Kodama et al [26] and Gianturco et a! [27].
Thirty X 10k" cells were collected by centrifugation at 1,200 rpm
for 10 minutes at room temperature, and the cell pellet was
solubilized in 0.3 ml of lysis solution containing 50 mivi Hepes, 1%
Triton X-100, 0.05% Twcen 20, 1.0 mi phenylmethylsulfonyl
fluoride, and 0.02 mg/mi leupeptin at pH 8.0 using a homogenizer.
Insoluble material was removed by centrifugation at 14,000 rpm
for 10 minutes at 4°C and the supernatant was used for the ligand
blot. Protein concentration was determined by the method of
Bradford using bovine serum albumin as a standard [28]. Equal
amounts of total cell protein (200 rg) was added to each lane and
subjected to electrophoresis on a 6% polyacrylamide slab gel
containing 0.1% SDS using the buffer system of Laemmli [29].
The proteins were subsequently electrotransferred to nitrocellu-
lose membranes at 5°C for 20 hours at 0.2 A. Complete transfer
was confirmed by Coomassie blue staining of the gel after the
transfer. The nitrocellulose membrane was incubated with block-
ing buffer (50 ms Tris-HCI, 2 ms'i CaCI2, 5% non-fat dry milk, and
90 mM NaCl at pH 8.0) for one hour while shaking at room
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temperature, incubated in 0.5% milk in the same buffer contain-
ing 30 jig/mi of Ac-LDL for three hours, and washed with buffer
without milk (3 times, 10 mm each). Ac-LDL bound to the
membrane was detected using affinity-purified goat anti-human
apolipoprotein B100 IgG (Biodesign international, Kennebunk,
ME, USA) followed by '251-labeled protein A (Amersham, Buck-
inghamshire, UK). The membrane was exposed to an imaging
plate (Fuji Film, Tokyo, Japan) for one hour and intensities of
protein bands were evaluated by the photostimulated lumines-
cence (PSL) values of the correspoding bands using Bio-Imaging
Analyzer BAS 2000 (Fuji Film). The data obtained were analyzed
by Image File Manager 3.0 software (Fuji Film).
RT-PCR followed by Southern blot analysis
SR mRNA type I and type II expression was separately
analyzed by RT-PCR and Southern blot analysis using the meth-
ods that we have previously described in detail [24]. Briefly, total
cellular RNA was extracted by the methods of Chomczynsky and
Sacchi [30] from 10 X 106 cells. One microgram of the total RNA
was reverse transcribed using Moloney murine leukemia virus
reverse transcriptase (Perkin-Elmer Cetus, Branchburg, NJ,
USA). The cDNA served as a template for PCR which was
performed using oligonucleotide primers for SR type I, type II,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an
internal control. Thirty microliters of each PCR reaction were
subjected to electrophoresis in a 2% agarose gel and nucleic acids
were transferred to a nylon membrane. The nylon membranes
were hybridized with 1 X 106 cpm/ml of 32P-labeled oligonucleo-
tide probes for SR and GAPDH. The blots were analyzed by
densitometry as described for the ligand blot analysis. Relative
PSL values (the ratio of SR to GAPDH) was used for the
semiquantitative comparison of the bands.
Determination of M-CSF levels in human serum
An M-CSF ELISA kit (Quantikine; R&D Systems Europe Ltd.,
Abingdon, UK) was employed for this analysis. A 96-well poly-
styrene microtiter plate was coated with a murine monoclonal
antibody against recombinant human M-CSF. The measurement
was based on the dual antibody immunometric sandwich principle
[31]. All samples and standards were assayed in duplicate accord-
ing to the manufacturer's protocol. The average of the duplicate
determinations was used for statistical analyses.
Neutralization of M-CSF activity in uremic serum
An optimal concentration in culture medium of the neutralizing
monoclonal antibody (mAb) to rM-CSF (anti-human M-CSF
neutralizing antibody; R&D Systems) was determined in our cell
culture system using 1 ng/ml of rM-CSF (R&D Systems) and flow
cytometry analysis. A HD serum mixture was pre-incubated with
an optimal concentration of mAb for 60 minutes at 3 7°C. The cells
were then cultured with the processed uremic serum for three
days and the SR activity was analyzed by flow cytometry, as
described above. As a control, the effect of an equivalent concen-
tration of normal mouse IgG2 (R&D Systems) was tested.
Statistical analyses
All data are presented as the mean SD. Statistical analyses
were performed using the Student's t-test. Statistical significance
was accepted if a P value was less than 0.05.
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Fig. 1. Specificity of the flow cytometty analysis of Dii labeled Ac-LDL
uptake in U937 cells. Excess amounts of unlabeled Ac-LDL inhibit uptake
of Dii labeled Ac-LDL by the U937 cells. The cells were incubated with
(A) 10 jig/mI unlabeled Ac-LDL (sMFI 15.3), (B) 10 jig/mI Dii labeled
Ac-LDL (sMFI 170.2), or (C) 10 jig/ml Dii labeled Ac-LDL plus 300
jig/mI unlabeled Ac-LDL (sMFI 20.2). Abbreviation sMFI is specific
mean fluorescence intensity.
Results
Effect of uremic serum on Dil-Ac LDL uptake by U937 cells
To assess the effect of uremic serum on SR activity, we
investigated the cellular internalization of Dii labeled Ac-LDL by
U937 cells incubated with 20% of different individual sera for
three days. Using flow cytometry analysis, the specificity of the
SR-mediated uptake of Dii labeled Ac-LDL was verified in a
competition assay in various human monocytic cell lines including
U937 [7, 32, 33]. The specificity of our experimental system was
established using a competition assay for cells cultured with
healthy serum as well as with uremic serum. A typical experiment
using a healthy serum is shown in Figure 1. A thirtyfold excess of
unlabeled Ac-LDL inhibited the uptake of 10 jig/mI of Dil-Ac
LDL by the U937 cells. Next, we evaluated the effect of HD
serum, CAPD serum, and healthy serum on SR activity; the
results are shown in Figure 2. The average sMFI was significantly
increased (P < 0.01) using HD serum (N = 10) or CAPD serum(N = 10), as compared to healthy serum (N = 10). There was a
1.7- (CAPD) to 1.9-fold (HD) increase in SR activity using uremic
serum, as compared to healthy serum. Although the mean sMFI
value using HD serum was slightly higher compared to CAPD
serum, no statistically significant difference was detected.
The stimulatory effect of uremic serum is cumulative, as shown
in Figure 3. The U937 cells were cultured in medium containing
0% (including 1% human albumin), 10%, 20%, or 30% of HD
serum mixture, or healthy serum mixture as described in the
Methods section. The experiments were performed in quadrupli-
cate. Uremic serum and healthy serum increased SR activity in a
dose-dependent manner. Using uremic serum, the increase of SR
100 102 io io
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Fig. 2. SR activity in U937 cells incubated with individual sera obtained
from HD patients, CAPD patients, and healthy subjects (N = 10 for each
group). SR activity was analyzed by uptake of Dii labeled Ac-LDL in U937
cells. Abbreviation sMFI is specific mean fluorescence intensity. Statisti-
cally significant differences are marked: *J) < 0.01 versus the healthy
serum. No statistically significant difference was observed between the HD
and the CAPD sera.
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Fig. 3. Cumulative effect of uremic serum on SR activity. U937 cells were
incubated with a HD serum mixture (0), a healthy serum mixture (•), 1%
albumin (0) or a mixture of 10% healthy and 10% HD serum (A). SR
activity was analyzed by flow cytometry. The cxperimcnts were performed
in quadruplicate. Abbreviation sMFI is specific mean fluorescence inten-
sity. Statistically significant differences are marked: * < 0.01 versus the
10% uremic serum mixture. #P < 0.01 versus the corresponding concen-
tration of healthy serum mixture. OP < 0.05 versus the 20% healthy serum
mixture.
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Fig. 4. Effect of heal-inactivation and ultrafiltration of the uremic serum
mixture on SR activity. The experiments were performed in quadruplicate.
Abbreviation sMFI is specific mean fluorescence intensity. Statistically
significant differences are P < 0.05 and ** < 0.01 versus the 20%
healthy serum mixture.
700
600
500
400
300
200
100
0
*
700
600
500
400
300
200
100
0
Healthy HD CAPD
0 10 20 30
600
500
400
300
200
100
0
activity was significantly higher with 30% serum compared to 10%
serum. Furthermore, each concentration of uremic serum signif-
icantly enhanced the SR activity compared to the corresponding
concentration of healthy serum. Healthy serum had a slightly
stimulating effect on SR activity, as compared to 1% albumin (P <
0.05, in both 20% and 30% healthy serum). The addition of 10%
uremic serum mixture to the 10% healthy serum mixture signifi-
cantly enhanced the effect on SR activity (P < 0.05 vs. the 20%
healthy serum). These results strongly suggest that the enhanced
SR activity observed in the U937 cells is not simply due to the
increased protein concentration in the medium, but to a substan-
ce(s) that is present in human serum and increased in uremic
serum.
Componetits in peripheral blood that may influence SR activity
lo elucidate possible component(s) in uremic serum that
mediate the stimulating effect on SR activity, we analyzed the
effects of heat-inactivation and ultrafiltration on uremic serum.
The data from experiments that were performed in quadruplicate
are presented in Figure 4. The 20% UF mixture did not show any
effect on SR activity, whereas the 20% heat-inactivated serum still
had a stimulatory effect compared to the 20% healthy serum
mixture. These results indicate that the serum component(s)
responsible for the enhanced SR activity was probably a heat-
stable factor(s) with a molecular weight greater than 10 kDa. To
assess the impact of platelet secretory products in serum, the
effect of 20% plasma was compared to that of the corresponding
serum in four HD, three cAPD, and two healthy individuals.
Platelet secretory products are generated in alpha-granules and
are enriched in serum as compared to plasma [3I. However, in
this study the plasma had almost the same impact as the serum in
all samples analyzed (data not shown).
Effect of uremic serum on SR protein amount
SR protein amount was examined by ligand blot in cells
cultured with the HD serum mixture, the CAPD serum mixture,
or the healthy serum mixture. The data are displayed in Figure 5.
Densitometry analyses showed that SR protein amount was
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Fig. 5. Ligand blot analysis for evaluating the effect of uremic serum on SR
protein amount. The cell membrane proteins were extracted from the
U937 cells cultured with 1% albumin (lane 1), 20% healthy serum mixture
(lane 2), 20% HD serum mixture (lane 3), and 20% CAPD serum mixture
(lane 4). The molecular size of SR is 220 to 240 kDa [91.
increased 1.4-fold in the presence of the HD serum mixture and
1.3-fold by the CAPD serum mixture, as compared to the healthy
serum mixture. The healthy serum mixture was comparable to 1%
albumin.
Effect of uremic serum on SR mRNA expression
In our previous study using primary monocyte-macrophages
[24], uremic serum might have enhanced SR type I mRNA
expression. Therefore, SR type I and type II mRNA expression
was studied in the U937 cells cultured with the same serum
mixtures tested in flow cytometry and ligand blot. The U937 cells
expressed both types of SRs in the absence of any stimulatory
reagents for cell differentiation. The HD serum mixture increased
type I mRNA expression 2.2-fold and type II mRNA 1.1-fold, as
compared to the healthy serum mixture, whereas the CAPD
serum mixture increased type I mRNA expression 1.9-fold and
type II mRNA 1.2-fold (Fig. 6). Total SR mRNA expression (the
sum of types I and II) increased 1.5-fold in using either the FID
serum mixture or the CAPD serum mixture, as compared to the
healthy serum mixture. The healthy serum mixture increased total
mRNA 1.2-fold compared to 1% albumin. The uremic serum
mixture thus predominantly enhanced SR type I mRNA.
M-CSF levels in uremic serum
M-CSF is a possible candidate that may he responsible for the
stimulation of SR activity in monocyte-macrophages of dialysis
patients [9, 16]. We measured the serum M-CSF levels in the
individual HD, CAPD and healthy sera. The mean serum level of
M-CSF in the HD patients was 3.47 0.81 ng!ml (range 2.57 to
4.81, N = 10), the level was 3.29 1.10 ng/ml (range 2.01 to 5.53,
N = 10) in the CAPD patients, and the level was 0.87 0.20 ng/ml
(range 0.47 to 1.09, N = 10) in the healthy subjects. The levels of
M-CSF in HD and CAPD serum were significantly higher than
the levels measured in healthy serum. A significant correlation
between serum M-CSF levels and SR activity evaluated by flow
cytometry was obtained in the pooled group of cells treated with
uremic serum (r = 0.785, P < 0.001, Fig. 7). In contrast, no
significant correlation was observed in the group of cells treated
with healthy serum.
Inhibitory effect of a neutralizing mAb to rM-CSF on uremic
serum
The effect of a neutralizing mAb to rM-CSF on SR activity was
tested in U937 cells cultured with a HD serum mixture or rM-CSF
using flow cytometry analysis. A total of 20% of the HD serum
mixture included in the culture medium, resulting in a concentra-
tion of M-CSF of 0.96 nglml, showed almost the same effect on SR
activity as I ng/ml of rM-CSF. Preincubation of the uremic serum
or the rM-CSF with the optimal concentration of mAb (10 ngiml)
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Fig. 6. Southern blot analysis of RT-PCR products of SR type I, SR type II,
and GAPDH. Total RNA was extracted from the U937 cells cultured with
1% albumin (lane 1), 20% healthy serum mixture (lane 2), 20% HD serum
mixture (lane 3), and 20% CAPD serum mixture (lane 4).
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Fig. 7. Correlation between serum levels of M-CSF and SR activity in U937
cells treated with healthy or uremic serum. Cells were incubated with healthy
serum (El), HD serum (0), or CAPD serum (5). A significant correlation
was observed only in the pooled group of cells incubated with uremic
serum. The regression line is shown (r = 0.785, P < 0.001).
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Fig. 8. Inhibition of the effect of uremic serum on SR activity in U937 cells
using a neutralizing monoclonal antibody to rM-CSF. Abbreviations are: C,
1% albumin; M, 1.0 ng/ml of rM-CSF; U, 20% of HD serum mixture; Ab,
10 ng/ml of monoclonal antibody to rM-CSF; and IgG, 10 nglml of normal
mouse IgG2. The experiments were performed in quadruplicates. Statis-
tically significant differences are *D < 0.01 versus M and #P < 0.02 versus
U.
suppressed their effect on SR activity to the control levels. The
inhibitory effect of the mAb was more pronounced using rM-CSF
compared to uremic serum. The equivalent concentration of
normal mouse 1gG2 did not show any suppressive effect (Fig. 8).
The inhibitory effect of the mAb was not due to toxic effects, since
more than 90% of the cells cultured with 50 ng/ml of the mAb
were viable in the presence or absence of uremic serum or
rM-CSF.
Activity of M-CSF fbllowing exposure to heat
Native M-CSF is a 90 kDa disulfide-linked homodimer. The
heat stability of native M-CSF dimer formation and activity is not
known. We examined the change of rM-CSF concentrations in
PBS following exposure to heat at 20°C, 56°C, and 100°C by
ELISA. rM-CSF concentrations gradually but very slightly de-
creased until 80°C and then reached undetectable levels at 100°C.
Native M-CSF in uremic serum remained stable after the process
of heat-inactivation at 56°C (the M-CSF levels changed from 3.53
ng/ml to 3.02 ng/ml after the process).
Discussion
Numerous atherogenic risk factors including hypertension, de-
teriorated calcium and phosphorous metabolism, platelet dysfunc-
tion, and dyslipirlemia are present in dialysis patients [22, 351. In
fact, patients with end-stage renal disease have excessive cardio-
vascular morbidity and mortality [20, 211. However, the mecha-
nism of uremia-associated atherosclerosis is not fully understood.
We previously reported that SR activity was enhanced in primary
monocyte-macrophages obtained from dialysis patients [241. In
this study, we show that uremic serum enhances SR mRNA
expression, protein amount, and activity in non-uremic monocytic
cells. In addition, we suggest that the elevated concentration of
M-CSF in uremic serum could be involved in the enhancement of
SR activity. Up-regulation of SR activity may thus significantly
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accelerate initiation and/or progression of atherosclerosis in dial-
ysis patients.
The characteristics of U937 cells have been well documented in
a variety of studies concerning immunology, lipidology, and
cancer [36—381. To study the effect of uremic serum on SR
expression and activity, we selected the U937 cell line. The U937
cells have a clear advantage in this study, as compared to primary
monocyte-macrophages since: (1) the supplement of autologous
serum into medium is essential for developing a solid cell culture
system in primary monocytes; and (2) in the primary cell culture
system, observations have occasionally shown that immunological
cell-serum interactions cause a premature cell death or cell
aggregation, possibly due to the anti-HLA antibodies present in
uremic serum. The immunologically related problems were never
observed when U937 cells were cultured with uremic serum.
C C+Ab M M+Ab U U+Ab U U+lgG The stimulation of SR activity by HD serum was slightly higher
than the increase of the protein amount or total SR mRNA
expression (1.8- vs. 1.4-, and 1.5-fold, respectively). Dii labeled
Ac-LDL is internalized through SR-mediated endocytosis and is
delivered to lysosomes for degradation. Dil is retained in lysoso-
mal membranes for several days [39]. The increased SR activity
shown in our study thus indicates that uremic serum not only
increases SR protein, but also stimulates the rate by which the SRs
endocytose Ac-LDL [9, 151. In a previous study [241, SR mRNA
and activity were studied in primary uremic macrophages that
were cultured with 20% autologous uremic serum. SR activity in
primary uremic macrophages was increased to the same extent as
in the U937 cells in this study. Also, the SR type I was predom-
inantly enhanced in the primary uremic cells as well as the U937
cells, as judged by RT-PCR. Our interpretation is that primary
macrophages and U937 cells may be subject to a similar regula-
tory mechanism by factor(s) in uremic serum, probably leading to
a transcriptional activation of SR genes. Taken together, uremic
serum has a clear stimulatory effect on SR activity principally
through transcriptional enhancement of the SR genes, especially
of type I, in both non-uremic and uremic monocyte-macrophage
lineage cells.
Our initial characterization of a stimulatory factor(s) for SR
activation suggests that it may be a heat-stable substance(s) with
a molecular weight greater than 10 kDa. Interestingly, M-CSF
levels were fourfold higher in both HD and CAPD serum
compared to healthy serum. Earlier studies showed that rM-CSF
stimulates the Ac-LDL metabolism through a SR-mediated pro-
cess [9, 151. Ishibashi et al [91 showed that rM-CSF dose-
dependently enhanced the uptake and degradation of Ac-LDL by
increasing the SR protein synthesis. Moreover, de Villiers et al
[151 showed that rM-CSF enhanced the SR in the murine
peritoneal macrophages at several different levels: message, pro-
tein synthesis as well as protein stability. Also, M-CSF stimulation
redistributed the intracellular pool of SR protein to the cell
surface, leading to a facilitated cellular Ac-LDL uptake. M-CSF
activates monocyte-macrophages in the picomolar range [141. Our
estimated concentration of M-CSF in the culture medium of
uremic serum was approximately 0.7 ng/ml (at a 20% concentra-
tion of uremic serum), which was within the range of stimulating
SR activity, according to the data by ishibashi et al [9]. Moreover,
the suppressive effect of a neutralizing mAb on uremic serum
strongly suggests that M-CSF in the uremic serum was responsible
for the enhancement of SR activity. The M-CSF level in uremie
serum remained stable after the process of heat-inactivation,
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which might explain why the heat-inactivated serum maintained a
stimulatory effect on SR activity. It is reasonable to assume that
the ultrafiltrate lost the stimulatory effect by a loss of M-CSF
molecules since the M-CSF level in the UF was below the
detection level of the ELISA kit. Finally, the serum levels of
M-CSF significantly correlated with the SR activity in the group of
cells treated with uremic serum. Taken together, the elevated
M-CSF concentration in uremic serum could account for the
enhancement of SR activity observed in this study.
Activated platelets release a variety of substances that have
been shown to affect lipoprotein metabolism in macrophages [10,
36, 401. Platelet secretory products have recently been shown to
stimulate SR activity [10, 34]. These products are generated in
alpha granules of the platelets and increased the SR activity and
expression after being internalized via the SR [10]. Alpha granules
of the platelets have been shown to be activated in HD patients
during the dialysis procedure by increased levels of P-selectin,
another protein stored in alpha granules [41]. Our comparison of
uremic plasma with uremic serum, which is more enriched in the
platelet secretory products [33], showed that the effect of plasma
was almost identical to that of serum in all of the blood samples.
We therefore suggest that platelet secretory products are less
relevant to the SR activation observed in our present study.
In conclusion, we have shown that uremic serum contains a
factor(s) with a molecular weight greater than 10 kDa that
enhances SR expression and activity in U937 cells. We suggest
that the elevated M-CSF level in uremic serum could be a
responsible factor for the enhancement of SR activity. SR may
play a key role in the development of uremia-associated athero-
sclerosis.
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